Editorial: Upadacitinib in Perianal Crohn's Disease. Authors' Reply
Alimentary Pharmacology & Therapeutics · 2026-08 · 64 (4) · 546-547
DOI: 10.1111/apt.70817 ↗At a glance
Editorial in Alimentary Pharmacology & Therapeutics, published online on 2026-06-20. Written by Nicolas Richard and 1 co-authors. Institution: Department of Gastroenterology, Univ Rouen Normandie, INSERM, ADEN UMR1073, "Nutrition, Inflammation and Microbiota-Gut-Brain Axis", CHU Rouen, Rouen…. Cited 1 times so far (Crossref); 7 references. The full text is freely available in PubMed Central.
Abstract (original language)
Abstract non disponibile.
Authors and institutions
- Department of Gastroenterology, Univ Rouen Normandie, INSERM, ADEN UMR1073, "Nutrition, Inflammation and Microbiota-Gut-Brain Axis", CHU Rouen, Rouen, France.
- Department of Gastroenterology, Amiens University Hospital and PeriTox, Université de Picardie, Amiens, France.
Cite
APA
Richard, N., & Fumery, M. (2026). Editorial: Upadacitinib in Perianal Crohn's Disease. Authors' Reply. Alimentary Pharmacology & Therapeutics, 64(4), 546-547. https://doi.org/10.1111/apt.70817
Vancouver
Richard N, Fumery M. Editorial: Upadacitinib in Perianal Crohn's Disease. Authors' Reply. Alimentary Pharmacology & Therapeutics. 2026;64(4):546-547. doi:10.1111/apt.70817
BibTeX
@article{Richard2026,
author = {Richard, Nicolas and Fumery, Mathurin},
title = {Editorial: Upadacitinib in Perianal Crohn's Disease. Authors' Reply},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2026},
volume = {64},
number = {4},
pages = {546--547},
doi = {10.1111/apt.70817}
}
EUVIMED